• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fractyl raises $44m Series D for Revita DMR tech

November 30, 2017 By Sarah Faulkner

FractylFractyl Laboratories said today that it raised $44 million in a Series D round, led by an undisclosed investor and first-time investors GV, True Ventures and the IDO Fund.

Returning investors included Deerfield Management Company, Bessemer Venture Partners and others. The company said it plans to use the round’s proceeds to fund the continued development of its Revita duodenal mucosal resurfacing procedure for people with Type II diabetes.

“Metabolic diseases, including Type II diabetes and NAFLD/NASH are an epidemic of staggering proportions, impacting hundreds of millions of people around the globe,” Dr. Krishna Yeshwant, general partner at GV, said in prepared remarks. “Fractyl offers the potential to fundamentally redefine the treatment paradigm for Type II diabetes and reverses the disease process rather than manage its symptoms.”

“More than 50 new drugs have been approved to manage Type II diabetes, yet too many patients still remain unable to control their disease and are at risk for serious complications from their disease” Fractyl’s co-founder & CEO Dr. Harith Rajagopalan added. “At Fractyl we have developed a minimally invasive, catheter-based procedural therapy that we believe can help reverse Type II diabetes and NASH.”

Changes to the lining of the duodenum can cause insulin resistance and metabolic diseases, including Type II diabetes, according to Fractyl.

The company’s minimally-invasive technology is designed to rejuvenate the surface of the duodenum using an endoscopic catheter-based procedure. The Revita DMR therapy, which has CE Mark clearance, can be performed in less than one hour and enables patients to resume normal activities the next day, Fractyl touted.

“Our unwavering aim is to develop technology to address the root cause of metabolic diseases in the intestine and enable the reversal of these diseases,” Rajagopalan said. “Our initial focus is to provide a compelling new treatment option for patients with poorly controlled Type II diabetes who are at risk of complications.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Featured, Funding Roundup Tagged With: fractyllaboratories

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS